WO2000065034A3 - Pseudotyped retroviral vector for gene therapy of cancer - Google Patents

Pseudotyped retroviral vector for gene therapy of cancer

Info

Publication number
WO2000065034A3
WO2000065034A3 PCT/CA2000/000445 CA0000445W WO0065034A3 WO 2000065034 A3 WO2000065034 A3 WO 2000065034A3 CA 0000445 W CA0000445 W CA 0000445W WO 0065034 A3 WO0065034 A3 WO 0065034A3
Authority
WO
WIPO (PCT)
Prior art keywords
retroviral
gene
cancer
pseudotyped
vsvg
Prior art date
Application number
PCT/CA2000/000445
Other languages
French (fr)
Other versions
WO2000065034A2 (en
Inventor
Jacques Galipeau
Original Assignee
Ct For Translational Res In Ca
Jacques Galipeau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct For Translational Res In Ca, Jacques Galipeau filed Critical Ct For Translational Res In Ca
Priority to EP00920308A priority Critical patent/EP1173551A2/en
Priority to CA002371216A priority patent/CA2371216A1/en
Priority to AU40961/00A priority patent/AU4096100A/en
Publication of WO2000065034A2 publication Critical patent/WO2000065034A2/en
Publication of WO2000065034A3 publication Critical patent/WO2000065034A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to retroviral expression vectors and more particularly to pseudotyped retroviral vectors for gene therapy of cancer. Direct in vivo tumor-targeting with 'suicide' viral vectors is limited by inefficient gene transfer and indiscriminate transfer of a contitionally toxic gene to surrounding non-malignant tissue. Retrovectors pseudotyped with a Vesicular Stomatitis Virus G protein (VSVG) may serve as a remedy to this conundrum. These retroviral particles differ from standard murine retroviruses by their very broad tropism and the capacity to be concentrated by ultracentrifugation without loss of activity. A VSVG-typed retrovector can be utilized for efficient and tumor specific Herpes Simplex Virus Thymidine Kinase (TK) gene delivery in vivo. A bicistronic retroviral vector which expresses TK and Green Fluorescence Protein (pTKiGFP) was constructed.
PCT/CA2000/000445 1999-04-23 2000-04-20 Pseudotyped retroviral vector for gene therapy of cancer WO2000065034A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00920308A EP1173551A2 (en) 1999-04-23 2000-04-20 Pseudotyped retroviral vector for gene therapy of cancer
CA002371216A CA2371216A1 (en) 1999-04-23 2000-04-20 Pseudotyped retroviral vector for gene therapy of cancer
AU40961/00A AU4096100A (en) 1999-04-23 2000-04-20 Pseudotyped retroviral vector for gene therapy of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13068099P 1999-04-23 1999-04-23
US60/130,680 1999-04-23

Publications (2)

Publication Number Publication Date
WO2000065034A2 WO2000065034A2 (en) 2000-11-02
WO2000065034A3 true WO2000065034A3 (en) 2001-01-25

Family

ID=22445832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000445 WO2000065034A2 (en) 1999-04-23 2000-04-20 Pseudotyped retroviral vector for gene therapy of cancer

Country Status (4)

Country Link
EP (1) EP1173551A2 (en)
AU (1) AU4096100A (en)
CA (1) CA2371216A1 (en)
WO (1) WO2000065034A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002310969A1 (en) * 2001-03-21 2002-10-03 Ipf Pharmaceuticals Gmbh Reporter virus comprising heterologous envelope proteins
US9175309B2 (en) 2001-09-29 2015-11-03 Industry-University Cooperation Foundation Hanyang University Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
WO2005038035A2 (en) * 2003-10-15 2005-04-28 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses
CN102978239A (en) * 2012-12-12 2013-03-20 广西壮族自治区水产研究所 Method for constructing two novel prawn expression vectors
WO2020043765A1 (en) * 2018-08-30 2020-03-05 Miltenyi Biotec Gmbh Ldlr negative packaging cell line for the production of vsv-g pseudotyped retroviral vector particles or virus particles thereof
CN113717990B (en) * 2021-08-30 2023-08-15 武汉大学 Novel vesicular stomatitis pseudovirus system based on double reporter genes and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004026A2 (en) * 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
CA2196208A1 (en) * 1994-08-17 1996-02-22 Michael Pensiero Retroviral vectors produced by producer cell lines resistant to lysis by human serum
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004026A2 (en) * 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GALIPEAU J. ET AL.: "Vesicular stomatitis virus G pseudotyped retrovirus mediates effective in vivo suicide gene delivery in experimental brain cancer", CANCER RESEARCH, vol. 59, 15 May 1999 (1999-05-15), pages 2384 - 2394, XP000926033 *
NALBANTOGLU J., ET AL.: "VSV-G PSEUDOTYPED RETROVECTOR MEDIATES HIGH EFFICIENCY IN VIVO GENETRANSFER IN GLIOMA-TARGETED SUICIDE GENE DELIVERY.", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 52., 12 April 1999 (1999-04-12), US, pages A425., XP000964616, ISSN: 0028-3878 *
ORY D S ET AL: "A STABLE HUMAN-DERIVED PACKAGING CELL LINE FOR PRODUCTION OF HIGH TITER RETROVIRUS/VESICULAR STOMATITIS VIRUS G PSEUDOTYPES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, no. 21, 15 October 1996 (1996-10-15), pages 11400 - 11406, XP002030515, ISSN: 0027-8424 *
See also references of EP1173551A2 *

Also Published As

Publication number Publication date
CA2371216A1 (en) 2000-11-02
EP1173551A2 (en) 2002-01-23
AU4096100A (en) 2000-11-10
WO2000065034A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
Walther et al. Viral vectors for gene transfer: a review of their use in the treatment of human diseases
Phillips The challenge of gene therapy and DNA delivery
AU707208B2 (en) Method for the preparation of a viral vector by intermolecular homologous recombination
Wildner et al. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
EP1232276B1 (en) Vectors and transgenes with regulatory elements for gene delivery to the liver
US8034620B2 (en) Lentiviral packaging cells and uses therefor
AU2020203408B2 (en) Improved thymidine kinase gene
WO2002101057A8 (en) Gene transfer into primate embryonic stem cells using vsv-g pseudo type simian immunodeficiency virus vector
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
EP0606376B1 (en) Method for genetically modifying bone marrow cells of primates, and useful cells therefor that produce recombinant retroviral vectors
WO2000065034A3 (en) Pseudotyped retroviral vector for gene therapy of cancer
DE69733035D1 (en) Chimäres retrovirus/adenovirus system
US5772993A (en) Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
Wilson Vectors-shuttle vehicles for gene therapy.
JP3953458B2 (en) Methods and compositions for therapy using genes encoding secreted proteins such as interferon beta
GB2368846B (en) Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
Kawakami et al. Liver-and lobe-selective gene transfection following the instillation of plasmid DNA to the liver surface in mice
US6303380B1 (en) Construction of retroviral producer cells from adenoviral and retroviral vectors
Kerr et al. Gene therapy: current status and future prospects
Wang et al. Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells
Zhang et al. Gene therapy for gastric cancer: a review
Searle et al. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene
RU2006123079A (en) VIRUS PARTICLES CONTAINING A VECTOR ORIGINING FROM ALPHAVIRUS AND METHOD FOR PRODUCING THE SPECIFIED VIRUS PARTICLE
Wysocki et al. Recent developments in retroviral gene delivery systems
US6130089A (en) Materials and methods for gene transfer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371216

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2371216

WWE Wipo information: entry into national phase

Ref document number: 2000920308

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920308

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10009512

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000920308

Country of ref document: EP